SCHEMBL6348984

SCHEMBL6348984

CN1CCCN(c2cnc3ccccc3c2)CC1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 6/20 0.89
CHRNB2 P17787 1/20 0.63
CHRNA4 P43681 1/20 0.63
MET P08581 5/20 0.56
DHFR P00374 1/20 0.55
AKR1C3 P42330 1/20 0.53
HRH4 Q9H3N8 3/20 0.52
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
CNR2 P34972 2/20 0.47
CNR1 P21554 1/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
XBP1 P17861 1/20 0.47
RAB9A P51151 1/20 0.47
KLF5 Q13887 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352883 0.94 HTR3A (1.00) HTR3ACHRNB2CHRNA4METDHFR
SCHEMBL8147076 0.85 CHRNB2 (0.73) HTR3ACHRNB2CHRNA4DHFRAKR1C3
SCHEMBL15257659 0.83 HTR3A (0.62) HTR3ACHRNB2CHRNA4METHRH4
SCHEMBL14783356 0.82 HTR3A (0.60) HTR3ACHRNB2CHRNA4METHRH4
Trifluoroacetic Acid SCHEMBL4522904 0.82 HTR3A (0.76) HTR3ACHRNB2CHRNA4METDHFR
SCHEMBL4219126 0.82 GAA (0.60) HTR3AMETHRH4KDM4ENPC1
SCHEMBL14783723 0.79 HTR3A (0.56) HTR3AMETHRH4NPC1MAPT
SCHEMBL17144739 0.77 HTR3A (0.87) HTR3ADRD3KDM4ENPC1MAPT
Oxalic Acid SCHEMBL8147179 0.77 CHRNB2 (0.63) HTR3ACHRNB2CHRNA4DHFRAKR1C3
SCHEMBL6353476 0.77 CHRNB2 (1.00) HTR3ACHRNB2CHRNA4DHFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 HTR3A 585/4885CHRNB2 700/4885CHRNA4 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.